Skip to content
AnalystLens

OHI · Omega Healthcare Investors

452 filings

OHI SEC Filings

Omega Healthcare Investors - 452 total filings

Filing record · 2016–202610-K1210-Q348-K126

OHI filed 12 annual reports (10-K), 34 quarterly reports (10-Q) and 126 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · Sep ’19Sep ’19
  3. Leadership change8-K · Jan ’22Jan ’22
  4. Leadership change8-K · Jan ’26Jan ’26
Showing 1–50 of 452 filings
10-Q

Omega Healthcare Investors Quarterly Report for Q3 Ended Sep 30, 2026

Omega Healthcare Investors, Inc. ("Parent"), a Maryland REIT with operations in the U.S., U.K. and Canada, reported net income of $86.8 million for the third quarter of 2026, down from $185.0 million in the same period of 2025, and net income available to common stockholders of $83.1 million, or $0.27 per diluted share, versus $0.59 a year earlier. For the nine months ended September 30, 2026, net income was $625.1 million ($1.92 diluted EPS), driven largely by a $249.1 million net gain on assets sold from the sale of 31 facilities. Total revenues rose to $340.6 million for the quarter from $311.6 million, with new resident fees and services of $30.8 million from the Company's RIDEA-structured Operating segment. Quarterly results were weighed down by $59.9 million of acquisition, merger and transition related costs, tied largely to the acquisition of operators of 30 U.K. care homes, and $39.6 million of general and administrative expense, which included non-cash stock-based compensation tied to leadership transitions. The balance sheet grew to $10.12 billion in total assets at September 30, 2026, with total equity of $5.76 billion and senior notes and other unsecured borrowings of $4.02 billion. Cash and cash equivalents increased to $195.9 million, and the revolving credit facility balance was zero, versus $242.0 million at year-end 2025. Management reports $2.0 billion of availability under its revolving credit facility and $1.8 billion of remaining ATM Program capacity. Operating cash flow for the nine months was $624.2 million. The company paid $605.4 million in common dividends during the nine months and declared a $0.68 per share dividend on October 26, 2026, payable November 16, 2026. Several subsequent events are disclosed. On October 1, 2026, the Company completed the transition of a 32-SNF Florida portfolio to PACS Group, Inc., paying a $90.0 million lease termination fee, with new initial annual contractual rent of $58.0 million under the PACS lease. Genesis's sale to NewGen closed on October 14, 2026, and the DIP loan and secured term loan claims were repaid in October 2026. The Company also funded a £631.7 million mortgage loan in November 2026 secured by the Runwood Portfolio, and it acquired a Georgia continuing care retirement community for $50.5 million on November 2, 2026. Leadership is also changing: Matthew P. Gourmand becomes President and CEO effective October 1, 2026, succeeding C. Taylor Pickett.

Nov 4, 2026
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Nov 3, 2026)

Omega Healthcare Investors, Inc. ("Omega") furnished a press release on November 3, 2026 reporting third quarter 2026 results. Net income was $87 million, or $0.27 per diluted share, versus $0.60 per basic share... more precisely, net income available to common stockholders was $83.1 million, or $0.27 per diluted share, for the quarter. AFFO was $262 million, or $0.82 per diluted share, compared with $243 million, or $0.79 per diluted share, in the third quarter of 2025. FAD was $250 million, or $0.78 per diluted share, versus $231 million, or $0.75 per diluted share, a year earlier. NOI rose to $332 million from $310 million. Investment activity was active. Omega completed $182 million of investments in the third quarter and $946 million since quarter-end, bringing 2026 year-to-date investment activity to approximately $1.5 billion. The largest post-quarter transaction was an $846 million U.K. mortgage loan to an affiliate of Foundation Partners Asset Management Limited, secured by 48 U.K. care homes and leasehold interests in 7 additional care homes, bearing interest at 8.72%. In October, Omega transitioned 32 Florida skilled nursing facilities to PACS Group, Inc. for a $90 million termination fee paid to the prior operator, adding $26.1 million of initial annual contractual rent. The Genesis Healthcare bankruptcy sale was finalized in October, with Omega's lease assumed by NewGen and $149.5 million received in repayment of DIP and term loans. Management raised its 2026 AFFO per diluted share guidance to $3.28 to $3.30, from $3.22 to $3.26, and declared a quarterly dividend of $0.68 per share payable November 16, 2026. As of September 30, 2026, total indebtedness was $4.1 billion at a weighted average interest rate of 4.2%, cash and cash equivalents were $195.9 million, and $2.0 billion was undrawn under the unsecured revolving credit facility. CEO Matthew Gourmand said leverage had been reduced to the lowest level in the Company's history.

Nov 3, 2026
8-K

Omega Healthcare Investors 8-K Report, Regulation FD Disclosure (Oct 5, 2026)

Omega Healthcare Investors, Inc. (NYSE: OHI) furnished an 8-K on October 5, 2026, under Item 7.01 (Regulation FD Disclosure), attaching a press release announcing a portfolio transition. According to the press release, Omega transitioned 32 skilled nursing facilities in Florida from an operator managed by affiliates of Airamid Health Services, LLC to subsidiaries of PACS Group, Inc. (NYSE: PACS), with an effective date of October 1, 2026. The information is furnished rather than filed and is not deemed incorporated by reference into other Company filings. The filing states that rent on this portfolio is scheduled to increase by $26.1 million in year one and by an additional $2.5 million in year two, with contractual 2% escalators thereafter. The portfolio will be added to Omega's existing master lease with PACS. Omega also incurred a one-time expense of approximately $90 million in connection with the transition. Management characterized the transaction as highly accretive for shareholders. CEO Matthew Gourmand described it as an example of Omega's active portfolio management, and CIO Vikas Gupta noted a relationship of over 15 years with Airamid and an intention to grow the relationship with PACS. The press release also includes standard forward-looking statement cautions.

Oct 5, 2026
8-K

Omega Healthcare Investors 8-K Report, Executive Changes (Oct 1, 2026)

Omega Healthcare Investors, Inc. (OHI) filed this Current Report on Form 8-K dated October 1, 2026, to disclose a leadership transition under Item 5.02. Effective October 1, 2026, the Board of Directors appointed Matthew P. Gourmand, the Company's President, as President and Chief Executive Officer, succeeding C. Taylor Pickett, who is retiring as CEO. The filing states that Mr. Pickett's retirement is not the result of any disagreement with the Company on its operations, policies or practices. The Board also appointed Mr. Gourmand as a director, filling the vacancy left by Mr. Pickett's retirement from the Board for the remainder of Mr. Pickett's term expiring in 2027. The number of directors on the Board remains at eight. The Board does not currently expect to appoint Mr. Gourmand to any committees. Mr. Gourmand, age 51, has been President since January 1, 2025, and previously served as Senior Vice President of Corporate Strategy & Investor Relations from January 2021 and as Senior Vice President of Investor Relations from October 2017. Before joining the Company, he worked as an equity portfolio manager, an equity research analyst, and in the audit department of Deloitte. The filing states he will receive no separate director compensation beyond what is provided under his employment agreement, and it discloses no related party transactions or family relationships requiring disclosure.

Oct 1, 2026
10-Q

Omega Healthcare Investors Quarterly Report for Q2 Ended Jun 30, 2026

Omega Healthcare Investors, Inc. reported net income of $379.7 million for the quarter ended June 30, 2026, compared with $140.5 million in the prior-year quarter, and net income available to common stockholders of $362.8 million, or $1.19 diluted earnings per share. Results were lifted by gains on asset sales of $246.5 million, driven mainly by the sale of 26 facilities in the quarter for total consideration of $562.6 million. Total revenues rose to $328.2 million from $282.5 million, led by rental income of $266.5 million and the first resident fees and services of $14.0 million from the new Operating segment. Net operating income (a non-GAAP measure) was $330.9 million, of which Triple-Net contributed $324.5 million and Operating $5.4 million. The balance sheet shows total assets of $10.01 billion, total equity of $5.64 billion and a revolving credit facility balance reduced to $6.0 million from $242.0 million at year-end 2025. Cash and cash equivalents were $39.0 million, and restricted cash rose to $145.2 million, including $117.7 million held by qualified intermediaries for pending 1031 exchanges. Operating cash flow for the six months was $433.2 million. The company also disclosed a leadership transition: CEO C. Taylor Pickett steps down October 1, 2026, with Matthew P. Gourmand succeeding him, and Robert O. Stephenson's employment ends August 1, 2026, with Neal A. Ballew becoming CFO. Management expects $31.8 million of incremental non-cash stock-based compensation tied to these arrangements, with a further $17.1 million expected in the third quarter. Credit and concentration items remain central to the outlook. Twenty-two operators were on a cash basis of rental revenue recognition, representing 22.2% of total revenues for the six months ended June 30, 2026. The Maplewood revolver, with an amortized cost of $263.6 million, is on non-accrual, and the Genesis bankruptcy continues, with the company's two secured term loans totaling $139.8 million expected to be satisfied upon plan effectiveness. The Board declared a quarterly dividend of $0.68 per share payable August 14, 2026.

Jul 30, 2026
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Jul 29, 2026)

Omega Healthcare Investors, Inc. (NYSE: OHI) reported second quarter 2026 results on July 29, 2026. Net income was $380 million, or $1.19 per diluted share, compared with $140 million, or $0.46 per diluted share, in Q2 2025. The quarter was lifted by a $246.5 million gain on assets sold, which accompanied the sale of 26 facilities for $562.6 million. Adjusted FFO was $261 million, or $0.83 per diluted share, compared with $232 million, or $0.77 per diluted share, a year earlier. FAD was $248 million, or $0.78 per diluted share, and NOI was $331 million, compared with $281 million in Q2 2025. Management stated that FAD per share rose 6.3% year over year. Omega completed $126 million of new investments in Q2 2026, mainly $110 million of real estate acquisitions and $16 million of real estate loan fundings, and completed another $93 million in July 2026. Management said the pipeline supports a significant increase in capital deployment through the rest of 2026 and into early 2027, although it does not provide specific acquisition guidance. The company also said it had transitioned 20 Ciena-operated Laurels skilled nursing facilities to new operators and the Saber PropCo JV, and that it holds a 9.9% equity interest in Saber. The board raised the quarterly common dividend by $0.01 to $0.68 per share, payable August 14, 2026, and the 2026 Adjusted FFO guidance range was increased to $3.22 to $3.26 per diluted share from $3.19 to $3.25. As of June 30, 2026, the company had $4.1 billion of outstanding indebtedness at a weighted average interest rate of 4.2%, cash of $39.0 million, and $2.0 billion of undrawn revolver capacity. The company also reported that Genesis, which filed for Chapter 11 in July 2025, has continued to make required contractual rent and interest payments through July 2026.

Jul 29, 2026
8-K

Omega Healthcare Investors 8-K Report, Shareholder Vote Results (Jun 5, 2026)

Omega Healthcare Investors, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, with holders of 255,926,290 common shares present in person or by proxy, representing approximately 85.93% of total outstanding common stock as of the record date. All three proposals passed: all eight director nominees (Kapila K. Anand, Craig R. Callen, Dr. Lisa C. Egbuonu-Davis, Barbara B. Hill, Kevin J. Jacobs, C. Taylor Pickett, Stephen D. Plavin and Burke W. Whitman) were elected, Ernst & Young LLP was ratified as independent registered public accounting firm for the year ending December 31, 2026 (240,521,117 for versus 14,949,017 against), and executive compensation was approved on an advisory basis (202,883,780 for versus 10,248,851 against). Under Item 8.01, the company updated its beneficial ownership disclosure for holders of more than 5% of its common stock. The filing explains that The Vanguard Group filed an amendment to its Schedule 13G on March 27, 2026, reporting it no longer had or was deemed to have beneficial ownership following an internal corporate realignment, and that two affiliated Vanguard entities subsequently reported beneficial ownership on a disaggregated basis. As of April 8, 2026, the filing lists BlackRock, Inc. with 31,867,200 shares (10.7% of class; 10.1% including common stock equivalents), Vanguard Portfolio Management with 27,160,324 shares (9.1%; 8.6%), and Vanguard Capital Management with 15,689,615 shares (5.3%; 5.0%). The company reported 297,799,835 common shares and 16,284,278 common stock equivalents (including OP Units) outstanding on that date.

Jun 5, 2026
8-K

Omega Healthcare Investors 8-K Report, Executive Changes (May 21, 2026)

Omega Healthcare Investors, Inc. (NYSE: OHI) announced a planned leadership transition in an 8-K filed May 21, 2026. Chief Executive Officer C. Taylor Pickett's employment and Board position will terminate effective October 1, 2026, and Matthew P. Gourmand, the Company's President, will become President and Chief Executive Officer on that date; Gourmand is also expected to join the Board. Chief Financial Officer Robert O. Stephenson's employment will terminate effective August 1, 2026, when Neal A. Ballew, the Senior Vice President and Chief Accounting Officer, becomes Chief Financial Officer and Lucas M. Golem, Vice President of Financial Reporting, becomes Chief Accounting Officer. The Board described the changes as reflecting upcoming retirement plans and long-term succession planning. Both departing executives entered into Transition Agreements and Release, and Consulting Agreements. Pickett will receive his 2026 short-term incentive earned on an un-prorated basis, equity awards vesting through December 31, 2029 on an un-prorated basis, COBRA-related health premium coverage for up to 18 months, and a $20,000 monthly consulting fee through October 1, 2027 (extendable at the Company's option to April 1, 2028). Stephenson receives payments and benefits tied to a termination without cause under his employment agreement, the 2026 short-term incentive on an un-prorated basis, equity vesting through December 31, 2029 on an un-prorated basis, and a $12,000 monthly consulting fee through August 1, 2027 (extendable to February 1, 2028). All benefits are conditioned on general releases and continued covenant compliance. The accompanying press release (Exhibit 99.1) quotes management describing the transition as a multi-year succession plan. It states that Stephenson leaves the Company as an investment-grade credit with a well-laddered maturity schedule and leverage near all-time lows, and it cites a total shareholder return of over 10,000% during Pickett's 25 years as CEO.

May 21, 2026
10-Q

Omega Healthcare Investors Quarterly Report for Q1 Ended Mar 31, 2026

Omega Healthcare Investors, Inc. reported first-quarter 2026 total revenues of $322.955 million, up from $276.785 million a year earlier, with rental income of $270.617 million and net income available to common stockholders of $151.049 million ($0.47 basic and diluted EPS, versus $0.34 basic and $0.33 diluted in Q1 2025). Growth was driven mainly by higher rental income from facility acquisitions, lease escalations, cash-basis operator payments (primarily Maplewood) and a stronger British Pound, partially offset by lower gains on asset sales ($3.0 million versus $10.1 million) and lower G&A, which benefited from a $6.6 million non-cash stock compensation charge in Q1 2025. Nareit FFO was $249.496 million versus $183.778 million in the prior-year quarter. The balance sheet expanded, with total assets of $10.23 billion at March 31, 2026, and the company drew more heavily on its revolver, which stood at $425.0 million versus $242.0 million at year-end 2025. Total unsecured borrowings were $4.44 billion, and the filing states that debt represented 45.1% of total capitalization. The company acquired 15 facilities for $126.4 million, made a $92.8 million investment for a 9.9% interest in Saber Healthcare Holdings, LLC, and issued 2.2 million shares through its ATM program for $106.7 million gross proceeds. Operating cash flow was $215.5 million. Credit and operator risk remain central. Twenty operators, representing 21.8% of total revenues for the quarter, were on a cash basis for rental revenue recognition. Maplewood remains on cash basis and non-accrual status, and Genesis is in Chapter 11, where the company has extended a Super-Priority DIP Loan of which $25.0 million was outstanding at quarter-end. A sale of Genesis' assets to WSSH is pending, with closing not expected before June 30, 2026. The company also declared a $0.67 per share dividend on April 23, 2026, payable May 15, 2026.

Apr 29, 2026
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Apr 28, 2026)

Omega Healthcare Investors, Inc. (NYSE: OHI) reported first quarter 2026 results on April 28, 2026, with net income of $159 million, or $0.47 per diluted share, compared to $112 million, or $0.33 per diluted share, in Q1 2025. Adjusted FFO was $260 million, or $0.82 per diluted share, on 315 million weighted-average diluted shares, versus $221 million, or $0.75 per diluted share, a year earlier. FAD was $247 million, or $0.78 per diluted share, compared to $211 million, or $0.71 per diluted share, in Q1 2025. Management stated that FAD per share rose 9.5% year over year. The company completed $251 million of new investments in Q1 2026, including $126 million in real estate acquisitions, $27 million in real estate loan fundings, and $97 million in unconsolidated entity investments, the largest being a 9.9% equity interest in Saber Healthcare Holdings for $93 million. It also issued 2 million common shares for gross proceeds of $107 million and completed $75 million of additional investments in April 2026. Omega announced the expected sale of 18 CommuniCare facilities in Q2 2026 for $480 million, which management said, once redeployed, would add a further three cents to FAD. Omega raised the low end of its 2026 Adjusted FFO guidance to a range of $3.19 to $3.25 per diluted share, from $3.15 to $3.25, moving the midpoint up by two cents to $3.22. The company had $4.5 billion of outstanding indebtedness at a weighted average interest rate of 4.2% as of March 31, 2026, and declared a quarterly dividend of $0.67 per share payable May 15, 2026. Genesis Healthcare, which is in Chapter 11, continued to make contractual rent and interest payments through April 2026, and Omega funded $25.0 million under a new DIP financing.

Apr 28, 2026
10-K

Omega Healthcare Investors Annual Report, Year Ended Dec 31, 2025

Omega Healthcare Investors, Inc. ("Parent") is a Maryland REIT that invests in healthcare-related real estate in the U.S., U.K. and Canada, with a portfolio of 1,027 operating healthcare facilities operated by 89 third-party operators or managers as of December 31, 2025. Total revenues rose to $1.19 billion in 2025 from $1.05 billion in 2024, net income was $609.5 million versus $417.8 million, and Nareit FFO was $898.9 million versus $733.9 million. Rental income increased to $1.00 billion and interest income to $175.1 million. Gains on assets sold were $67.3 million from the sale of 49 facilities for approximately $282.8 million in net cash proceeds. The balance sheet grew to $10.05 billion in total assets, with total debt of $4.3 billion and approximately 44.1% of total capitalization represented by debt. Cash and cash equivalents fell to $27.0 million from $518.3 million, and the company reported a weighted average debt interest rate of 4.2%. During 2025 the company issued $600 million of 5.200% senior notes due 2030, entered a $2.0 billion revolving credit facility and a $300.0 million 2028 Term Loan, redeemed $600.0 million of 5.250% notes, and sold 16.3 million shares under its ATM and DRCSPP programs for $612.1 million in gross proceeds. Dividends paid were $2.68 per share in 2025, and a $0.67 dividend was declared on January 29, 2026. Key risks disclosed include operator financial stress tied to Medicaid and Medicare reimbursement, including the OBBBA's estimated $920 billion in Medicaid cuts over the next decade; operator bankruptcies, notably Genesis Healthcare (Chapter 11 since July 2025) and LaVie; and concentration, with the U.K. at 17.7% and Texas at 8.5% of real estate assets and mortgages. Maplewood's cash-basis lease and restructured loan were also significant items. Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting.

Feb 9, 2026
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Feb 4, 2026)

Omega Healthcare Investors, Inc. (NYSE: OHI) reported fourth-quarter and full-year 2025 results in a press release furnished as Exhibit 99.1. For Q4 2025, net income was $172 million, or $0.55 per diluted share, versus $116 million, or $0.41 per diluted share, in Q4 2024. Adjusted FFO (AFFO) was $250 million, or $0.80 per diluted share, versus $214 million, or $0.74, and FAD was $238 million, or $0.76 per diluted share, versus $202 million, or $0.70. For full-year 2025, net income was $609 million, or $1.94 per common share, and AFFO was $946 million, or $3.10 per diluted share, compared with $2.87 in 2024. FAD was $903 million, or $2.96 per diluted share, versus $2.73 in 2024, which the CEO described as FAD per share growth of 8.4%. The company completed $1.1 billion of new investments in 2025, including $334 million in Q4, and repaid $1.7 billion of debt. It issued $600 million of 5.2% senior unsecured notes due 2030, entered a new $2.3 billion senior unsecured credit facility, and issued 16 million common shares and 5.5 million Omega OP Units for proceeds or value of $612 million and $222 million. At December 31, 2025, indebtedness totaled $4.3 billion at a weighted average interest rate of 4.2%, with $27.0 million of cash and $1.8 billion of undrawn revolver capacity. Management stated leverage reached the lowest level in the company's history. For 2026, Omega guided to Adjusted FFO of $3.15 to $3.25 per diluted share. The guidance assumes no additional operators are placed on a cash basis, Genesis continues paying its full contractual rent of $13.0 million per quarter, and Maplewood pays $6.5 million per month starting in February. The guidance excludes additional acquisitions, capital markets activity, and provisions for credit losses. The Board declared a quarterly dividend of $0.67 per share, payable February 17, 2026. A conference call is scheduled for February 5, 2026 at 10 a.m. Eastern Time.

Feb 4, 2026
8-K

Omega Healthcare Investors 8-K Report, Executive Changes (Jan 7, 2026)

Omega Healthcare Investors, Inc. reported in this Form 8-K, dated January 7, 2026, that effective January 1, 2026 it entered into amendments to the employment agreements of each of its named executive officers. The amendments extend each agreement's term by one year to December 31, 2028 and revise annual salaries following the annual review by the Compensation Committee of the Board of Directors. The filing states that the amendments also included material changes for Matthew Gourmand, President, and Gail Makode, Chief Legal Officer and General Counsel. For Mr. Gourmand, the filing states that the annual bonus opportunity was increased to 200% of base salary at the high level of performance (from 125%), 125% at target (from 75%), and 75% at threshold (from 50%). Severance upon termination without cause or for good reason, as defined in the agreement, rises from two times the sum of annual base salary and the three-year average annual bonus to three times that sum, payable over three years. His post-termination non-competition and non-solicitation covenants were extended from two years to three years. For Ms. Makode, the filing states that severance upon termination without cause or for good reason increases from one and a half times to two times the sum of annual base salary and the three-year average annual bonus, payable over two years, and her post-termination restrictive covenants were extended from 18 months to two years. The full text of the form of amendment is to be filed as an exhibit to the Company's Form 10-Q for the first quarter of 2026.

Jan 7, 2026
8-K

Omega Healthcare Investors 8-K Report, Corporate Update (Nov 3, 2025)

On November 3, 2025, Omega Healthcare Investors, Inc. entered into a new at-the-market (ATM) equity offering sales agreement with a broad group of sales agents, forward sellers and forward purchasers. The agreement covers the issuance and sale of shares of its common stock, par value $0.10 per share, together with forward shares, with aggregate gross sales not to exceed $2,000,000,000. On the same date, the company terminated its prior at-the-market equity offering sales agreement dated September 6, 2024. The company has no obligation to sell any securities under the agreement and may suspend offers at any time. Sales, if any, may occur on the New York Stock Exchange, in negotiated transactions, or by other methods permitted by law. Each sales agent's compensation will not exceed 2.0% of the gross sales price of shares it sells as agent, and forward sellers' commissions will not exceed 2.0% of the gross sales price of borrowed shares sold, paid through a reduced initial forward sale price. Under forward sale agreements, the company expects to physically settle by delivering shares and receiving proceeds no later than two years after entry into each agreement, but it may instead elect cash or net share settlement, in which case it may receive no proceeds. The securities are being offered under an automatic shelf registration statement on Form S-3 (No. 333-277916) and a prospectus supplement dated November 3, 2025. Several of the agents and their affiliates have provided and may continue to provide banking and advisory services to the company for customary fees.

Nov 3, 2025
10-Q

Omega Healthcare Investors Quarterly Report for Q3 Ended Sep 30, 2025

Omega Healthcare Investors, Inc. reported net income available to common stockholders of $179.7 million, or $0.59 diluted per share, for the three months ended September 30, 2025, compared with $111.8 million, or $0.42 diluted per share, a year earlier. For the nine months, net income available to common stockholders was $425.4 million, or $1.39 diluted per share, versus $293.0 million, or $1.14 diluted per share, in the prior-year period. Total revenues were $311.6 million for the quarter and $870.9 million for the nine months. Nareit FFO was $241.8 million for the quarter and $639.1 million for the nine months, compared with $196.1 million and $538.3 million a year earlier. The company's balance sheet grew over the period. Total assets were $10.6 billion at September 30, 2025, and total debt was $5.0 billion, representing 48.9% of total capitalization. Operating cash flow was $647.9 million for the nine months. Omega issued 8.8 million shares through its dividend reinvestment plan and 7.5 million through its at-the-market program during the nine months, and it acquired 66 facilities for $637.9 million. In September 2025 it replaced its $1.45 billion revolver with a $2.0 billion revolving credit facility and a $300.0 million delayed draw term loan. In October 2025 it redeemed $600.0 million of 5.250% senior notes at par. Credit quality remains a key watch item. Maplewood, which is on a cash basis and on non-accrual for interest on its $320 million revolver, paid $15.3 million of contractual rent for the quarter against $17.3 million due. Subsequent to quarter-end, the company entered into a joint venture with affiliates of Saber Healthcare Holdings and agreed to acquire a 9.9% equity interest in Saber for $92.6 million in cash, with closing expected January 1, 2026.

Oct 31, 2025
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Oct 30, 2025)

Omega Healthcare Investors, Inc. (NYSE: OHI) reported third quarter 2025 results on October 30, 2025 via a press release attached as Exhibit 99.1. Net income for the quarter was $185 million, or $0.59 per diluted share, versus $115 million, or $0.42 per diluted share, in Q3 2024. Adjusted FFO was $243 million, or $0.79 per diluted share, on 308 million weighted-average diluted shares, compared with $203 million, or $0.74 per diluted share, a year earlier. FAD was $231 million, or $0.75 per diluted share. Management raised its 2025 AFFO guidance to $3.08 to $3.10 per diluted share, up from $3.04 to $3.07, and the company cited roughly $756 million of year-to-date real property and loan investments plus a $222 million joint venture investment as supporting it. The quarter's activity centered on balance sheet management and investment. Omega closed a new $2.3 billion senior unsecured credit facility on September 30, 2025, consisting of a $2.0 billion four-year revolver and a $300.0 million three-year delayed draw term loan, which replaced the prior $1.45 billion facility. It also repaid $600 million of 5.25% senior unsecured notes at par on October 15, 2025, and extended a $428.5 million term loan to August 8, 2026. As of September 30, 2025, total indebtedness was $5.0 billion at a weighted average interest rate of 4.6%, and cash and cash equivalents were $737.2 million. In October 2025, the company formed a joint venture with affiliates of Saber Healthcare Holdings in which Omega acquired a 49% interest for Omega OP Units with a fair value of $222.4 million, covering 64 facilities that generate $69.4 million in annual contractual rent. A separate agreement to acquire a 9.9% equity interest in Saber's operating company for $92.6 million is expected to close January 1, 2026. Operator exposure remained a focus. Genesis Healthcare, which filed for Chapter 11 on July 9, 2025, made all required rent and interest payments in the third quarter and paid its full contractual rent and interest of $4.4 million in October 2025. The company also declared a quarterly dividend of $0.67 per share payable November 17, 2025. Operator coverage data showed twelve-month EBITDARM coverage before management fees of 1.91x and after management fees of 1.55x for the period ended June 30, 2025, with occupancy of 82.6%. Management described the backdrop as favorable and said the pipeline is very active.

Oct 30, 2025
8-K

Omega Healthcare Investors 8-K Report, Agreement Terminated (Oct 15, 2025)

Omega Healthcare Investors, Inc. ("Omega") reported under Item 1.02 (Termination of a Material Definitive Agreement) that on October 15, 2025 it redeemed all of its outstanding $600 million aggregate principal amount of 5.250% Senior Notes due 2026 (the "Notes"). The Notes were issued under an Indenture dated as of September 23, 2015, with U.S. Bank Trust Company, National Association as Trustee, and were guaranteed by certain of Omega's subsidiaries. As previously reported, the Trustee notified holders on September 15, 2025 of Omega's election to redeem the Notes on October 15, 2025. On that date Omega irrevocably deposited $607,875,000 with the Trustee to pay the redemption price, which equaled 100% of principal plus accrued and unpaid interest to, but not including, the redemption date. As a result, Omega's and the subsidiary guarantors' obligations under the Notes, the Indenture and the related guarantees terminated, and the Indenture was discharged, though customary provisions on Trustee compensation, indemnification and application of trust money survive. For investors, this is a routine debt retirement that removes the $600 million 2026 maturity from Omega's capital structure. The filing also discloses that U.S. Bank Trust Company, National Association has performed corporate trust services for Omega for customary compensation and may do so again.

Oct 15, 2025
8-K

Omega Healthcare Investors 8-K Report, Material Agreement (Oct 1, 2025)

On September 30, 2025, Omega Healthcare Investors, Inc. entered into a new senior unsecured $2.3 billion credit facility, consisting of a $2.0 billion multicurrency revolving credit facility and a $300.0 million delayed draw term loan (DDTL) facility. The Amended and Restated Credit Agreement, dated as of September 30, 2025, replaces Omega's previous $1.45 billion 2021 Revolving Credit Facility, which was scheduled to expire on October 30, 2025, and that prior facility was terminated. The Revolving Credit Facility matures on September 28, 2029, with two six-month extension options, and the DDTL Credit Facility matures on September 29, 2028, with two twelve-month extension options. The Credit Facility may be drawn in U.S. Dollars, Euros, British Pounds Sterling and Canadian Dollars, and Omega may increase maximum aggregate commitments to $3.0 billion, subject to customary conditions. Omega also entered into a First Amendment to its existing $428.5 million term loan credit agreement, dated August 8, 2023. The amendment reduces the interest rate margins to a range from 1.60% to 0.800% for SOFR-based loans and from 0.60% to 0% for base rate advances, and removes the 0.100% interest rate step-up for each extension period. The current maturity of the term loan is August 8, 2026, subject to one additional 12-month extension option. As of September 30, 2025, Omega had no borrowings outstanding under the new Credit Facility and $428.5 million outstanding under the Term Loan Credit Agreement. The Credit Agreement contains covenants setting maximum total leverage, maximum secured leverage, maximum unsecured leverage, minimum fixed charge coverage, minimum consolidated tangible net worth and minimum unsecured interest coverage. The filing states that Omega did not experience any material early termination penalties from terminating the prior revolver. Omega described the purposes of the new facility as refinancing existing indebtedness, financing acquisitions, and funding working capital, capital expenditures and other general corporate purposes.

Oct 1, 2025
8-K

Omega Healthcare Investors 8-K Report, Corporate Update (Sep 15, 2025)

Omega Healthcare Investors, Inc. (NYSE: OHI) announced on September 15, 2025 that it will redeem all of its outstanding 5.250% Senior Notes due 2026 on October 15, 2025. Per the press release (Exhibit 99.1), the outstanding aggregate principal amount is $600,000,000. The notes will be redeemed at 100% of principal amount, plus accrued and unpaid interest to, but not including, the redemption date. An irrevocable notice of redemption was mailed to record holders on September 15, 2025 by U.S. Bank Trust Company, National Association, the trustee under the indenture governing the notes. The filing describes the redemption as a standard action taken under the indenture's terms. The filing itself contains no information on the company's operating results, financial condition, or the funding source for the redemption. For investors, the key takeaway is the planned retirement of $600 million of debt in October 2025, with holders receiving par plus accrued interest. The filing describes Omega as a REIT investing in long-term healthcare, primarily skilled nursing and assisted living facilities, operated predominantly under triple-net leases across the United States and the United Kingdom.

Sep 15, 2025
10-Q

Omega Healthcare Investors Quarterly Report for Q2 Ended Jun 30, 2025

Omega Healthcare Investors, Inc. (Parent, a Maryland corporation, with its consolidated subsidiaries referred to as "Omega" or the "Company") reported its quarterly results for the period ended June 30, 2025 in this Form 10-Q. For the three months ended June 30, 2025, total revenues were $282.5 million versus $252.7 million a year earlier, and net income available to common stockholders was $136.6 million, or $0.46 per diluted share, compared with $113.9 million, or $0.45 per diluted share, in the prior-year quarter. For the six months ended June 30, 2025, net income available to common stockholders was $245.6 million, or $0.79 per diluted share. Rental income for the six months rose to $471.4 million from $421.2 million, and total assets reached $10.55 billion at June 30, 2025. The Company expanded its portfolio during the period, acquiring 63 facilities for $560.4 million in the six months ended June 30, 2025, including a 45-facility acquisition in the U.K. and Jersey for $344.2 million. It sold 34 facilities for $183.0 million in net cash proceeds and issued $600 million of 5.200% Senior Notes due 2030 in June 2025. Common shares outstanding rose to 293.1 million at June 30, 2025, and the Company paid $383.8 million in dividends during the six months. Cash and cash equivalents stood at $734.2 million at quarter end. Credit quality remained a concern. Maplewood is on a cash basis and short-paid rent, and its $320 million revolver is on non-accrual with no interest income recognized in the period. LaVie's plan of reorganization took effect June 1, 2025, and Genesis Healthcare filed for Chapter 11 in July 2025, after the period end, with the Company committing up to $8.0 million to a $30.0 million DIP financing. Twenty-two operators were on a cash basis of revenue recognition, representing 17.5% of total revenues for the six months ended June 30, 2025.

Aug 1, 2025
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Jul 31, 2025)

Omega Healthcare Investors, Inc. (NYSE: OHI) reported second-quarter 2025 results on July 31, 2025, with net income of $140 million, or $0.46 per common share, compared with $117 million, or $0.45 per share, in Q2 2024. Adjusted FFO was $232 million, or $0.77 per common share, on 303 million weighted-average diluted shares, compared with $185 million, or $0.71 per share, a year earlier. The company completed about $527 million of new investments in the quarter, including $502 million of real estate acquisitions, and issued $600 million of 5.2% senior unsecured notes due 2030. It also raised its 2025 AFFO guidance to $3.04 to $3.07 per diluted share, up from $2.95 to $3.01. The filing highlights the status of several operators. LaVie completed its bankruptcy effective June 1, 2025, and its master lease was assigned to Avardis, with the monthly rent unchanged at $3.1 million and Avardis recognizing rental income on a straight-line basis of $3.6 million per month. Genesis Healthcare filed for Chapter 11 on July 9, 2025. Omega agreed to provide an $8.0 million debtor-in-possession financing, which requires Genesis to pay full contractual rent, and the company expects to continue recognizing full rental and interest income from Genesis during the bankruptcy. The company also disclosed a $15.5 million non-cash straight-line receivable write-off tied to an operator moved to cash-basis revenue recognition after a going-concern doubt was raised. Balance sheet activity included total indebtedness of $5.0 billion at a weighted-average annual interest rate of 4.6% as of June 30, 2025, and cash and cash equivalents of $734.2 million. Omega declared a quarterly dividend of $0.67 per share payable August 15, 2025. Management described the backdrop as highly favorable, citing improving operating metrics, an active pipeline and a cost of capital that supports continued accretive investment.

Jul 31, 2025
8-K

Omega Healthcare Investors 8-K Report, Regulation FD Disclosure (Jul 10, 2025)

Omega Healthcare Investors, Inc. (NYSE: OHI) filed this Current Report on Form 8-K dated July 10, 2025 under Item 7.01 (Regulation FD Disclosure). The Company stated that it posted an updated investor presentation, titled "July 2025 Investor Presentation," to its website's Investor Relations and News & Events sections. The update consists of a revised Operator Updates slide. The presentation will remain on the website for at least thirty days. The disclosure is furnished rather than filed, so the information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other Company filings. The accompanying Exhibit 99.1 is a press release dated July 10, 2025 announcing the revised slide, and it describes Omega as a real estate investment trust investing in long-term healthcare, primarily skilled nursing and assisted living facilities, operated predominantly under triple-net leases across the US and the UK. The filing does not describe the substance of the revised Operator Updates slide, so investors seeking the content of the change will need to review the updated presentation itself. The filing contains no financial results or quantitative figures.

Jul 10, 2025
8-K

Omega Healthcare Investors 8-K Report, Material Agreement (Jun 20, 2025)

On June 20, 2025, Omega Healthcare Investors, Inc. ("Omega") completed an underwritten public offering of $600 million aggregate principal amount of its 5.200% Senior Notes due 2030. The Notes were sold at 99.118% of principal amount, mature on July 1, 2030, and pay interest semi-annually on January 1 and July 1, beginning January 1, 2026. The offering was made under Omega's automatic shelf registration statement on Form S-3 (Registration No. 333-282376) and a related prospectus supplement. Omega expects to use the net proceeds for general corporate purposes, which may include repaying existing indebtedness, pursuing future acquisition or investment opportunities in healthcare-related real estate, and paying offering fees and expenses. The Notes are unsecured senior obligations that rank equally with Omega's existing and future senior debt, are effectively subordinated to secured indebtedness to the extent of the collateral value, and are structurally subordinated to all liabilities of non-guarantor subsidiaries. They are guaranteed by OHI Healthcare Properties Limited Partnership and by future subsidiaries that guarantee unsecured debt of at least $100 million. The Indenture, with U.S. Bank Trust Company, National Association as trustee, includes covenants limiting additional indebtedness and mergers or asset sales, a covenant requiring a certain amount of unencumbered assets, and customary events of default, including cross-acceleration. Omega may redeem the Notes before June 1, 2030 at par plus a make-whole premium, and at par plus accrued interest on or after that date. The filing was signed by Chief Financial Officer Robert O. Stephenson.

Jun 20, 2025
8-K

Omega Healthcare Investors 8-K Report, Corporate Update (Jun 11, 2025)

Omega Healthcare Investors, Inc. ("Omega") priced an underwritten public offering of $600,000,000 aggregate principal amount of 5.200% Senior Notes due 2030 on June 10, 2025, as disclosed in this Current Report on Form 8-K dated June 11, 2025. The notes will mature on July 1, 2030, were issued at 99.118% of principal amount, and pay a fixed coupon of 5.200% per annum semiannually beginning January 1, 2026. Settlement is expected on June 20, 2025, subject to customary closing conditions. Net proceeds, after the underwriting discount but before estimated offering expenses, are expected to be approximately $591,108,000. Omega intends to use the net proceeds for general corporate purposes, which may include repaying existing indebtedness, pursuing future acquisition or investment opportunities in healthcare-related real estate properties, and paying certain fees and expenses related to the offering. The notes are guaranteed by OHI Healthcare Properties Limited Partnership and will be guaranteed by Omega's existing and future subsidiaries that guarantee unsecured indebtedness for money borrowed of Omega in a principal amount of at least $100 million. The offering is being made under a prospectus supplement filed on a Form S-3 shelf registration statement (Registration No. 333-282376). Wells Fargo Securities, LLC, BofA Securities, Inc., Credit Agricole Securities (USA) Inc. and J.P. Morgan Securities LLC are acting as joint book-running managers.

Jun 11, 2025
8-K

Omega Healthcare Investors 8-K Report, Corporate Update (Jun 6, 2025)

Omega Healthcare Investors, Inc. filed a Form 8-K on June 6, 2025 under Item 8.01 (Other Events) to report that it had filed a prospectus supplement for its existing Dividend Reinvestment and Common Stock Purchase Plan (the "Plan") under its automatic shelf registration statement on Form S-3ASR (No. 333-277916), originally filed March 14, 2024. The DRCSPP Prospectus Supplement continues the offering of the Company's common stock, par value $0.10 per share, under the Plan, which was previously covered by a prospectus supplement filed March 14, 2024. The supplement registers an aggregate of 22,447,054 shares of Common Stock for issuance under the Registration Statement. The Plan allows existing stockholders and interested new investors to purchase Common Stock and reinvest all or a percentage of their cash dividends in additional shares. The filing's exhibits consist of legal opinions from Shapiro Sher Guinot & Sandler, P.A. (Exhibit 5.1) and Bryan Cave Leighton Paisner LLP (Exhibit 8.1), along with related consents and the cover page interactive data file. The filing is administrative in nature and does not report financial results, dividends, or changes in the Company's financial condition. The 8-K states that it does not constitute an offer to sell or a solicitation of an offer to buy any securities. It was signed by Robert O. Stephenson, Chief Financial Officer, Treasurer and Assistant Secretary.

Jun 6, 2025
8-K

Omega Healthcare Investors 8-K Report, Bylaw Amendment (Jun 6, 2025)

On June 6, 2025, Omega Healthcare Investors, Inc. ("Omega" or the "Company") held its 2025 Annual Meeting of Stockholders, where stockholders approved an amendment to the Articles of Amendment and Restatement to increase authorized common stock, $0.10 par value per share, from 350,000,000 shares to 700,000,000 shares. The filing states that a summary of this amendment appeared in Proposal 4 of the definitive proxy statement filed April 22, 2025, as amended, and that the full text is filed as Exhibit 3.1. Holders of 242,057,737 shares, representing approximately 84.29% of total outstanding common stock as of the record date, were present in person or by proxy. All eight director nominees were elected, Ernst & Young LLP was ratified as independent auditor for fiscal year 2025, executive compensation was approved on an advisory basis, and the charter amendment was approved. For the charter amendment, 231,662,341 shares voted for, 8,905,260 against, and 1,490,136 abstained. Effective upon completion of the Annual Meeting, Stephen D. Plavin was appointed to the Investment Committee in place of C. Taylor Pickett and no longer serves on the Compensation Committee. The filing also lists the current membership of the Audit, Compensation, Investment, and Nominating and Corporate Governance Committees.

Jun 6, 2025
8-K

Omega Healthcare Investors 8-K Report, Regulation FD Disclosure (Jun 2, 2025)

Omega Healthcare Investors, Inc. (NYSE: OHI) filed a Current Report on Form 8-K dated June 2, 2025, under Item 7.01 (Regulation FD Disclosure). The company announced that it had posted an updated investor presentation titled "June 2025 Investor Presentation" to its website's Investor Relations and News & Events sections. The update consists of a revised Operator Updates slide. The presentation will remain on the company's website for at least thirty days. The filing is a disclosure-only notice. It furnishes the information under Regulation FD and states that it is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. The accompanying Exhibit 99.1 is a press release dated June 2, 2025, titled "Omega Issues Business Update," which announces the revised slide. The press release also describes Omega as a real estate investment trust investing in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities, with a portfolio operated predominantly under triple-net leases across all US regions and the UK. The filing contains no financial results, financial statements, or quantitative metrics. Its investor relevance is limited to the updated Operator Updates content in the investor presentation, which the filing does not describe in detail.

Jun 2, 2025
8-K

Omega Healthcare Investors 8-K Report, Regulation FD Disclosure (May 12, 2025)

Omega Healthcare Investors, Inc. (NYSE: OHI) filed a Current Report on Form 8-K dated May 12, 2025, under Item 7.01 (Regulation FD Disclosure). The company announced that it had posted an updated investor presentation titled "May 2025 Investor Presentation" to its website's Investor Relations and News & Events sections. The update consists of a revised Operator Updates slide. The presentation will remain on the company's website for at least thirty days. The announcement is communicated through a press release attached as Exhibit 99.1, which describes Omega as a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities, with a portfolio operated predominantly under triple-net leases across all US regions and the UK. The press release itself does not disclose the substance of the revised Operator Updates slide, and the filing contains no financial results, guidance, or quantitative metrics. The information is furnished rather than filed, so it is not subject to Section 18 liabilities of the Securities Exchange Act of 1934. For investors, this filing is a routine disclosure of a presentation update, and the content of the revision would need to be reviewed directly in the investor presentation on the company's website.

May 12, 2025
10-Q

Omega Healthcare Investors Quarterly Report for Q1 Ended Mar 31, 2025

Omega Healthcare Investors, Inc. ("Parent"), a Maryland REIT with an UPREIT structure, reported net income of $112.1 million for the three months ended March 31, 2025, up from $69.3 million a year earlier, and net income available to common stockholders of $109.0 million, or $0.33 per diluted share, versus $0.27 in the prior-year quarter. Total revenues rose to $276.8 million from $243.3 million, driven mainly by higher rental income ($232.2 million vs. $206.9 million) and interest income ($43.1 million vs. $35.8 million). Results were supported by a $10.1 million net gain on the sale of 27 facilities for $120.9 million in net cash proceeds, partly offset by a $10.0 million lease inducement to a cash-basis operator recorded as a reduction of rental income and $6.6 million of non-cash stock-based compensation tied to a leadership transition. The balance sheet shrank over the quarter, with total assets of $9.71 billion versus $9.90 billion at December 31, 2024, as the company repaid $400 million of 4.50% senior notes at maturity and reduced cash to $368.0 million. Total debt was $4.45 billion, with a weighted average annual interest rate of 4.6% and 94.7% of debt with outstanding principal having fixed interest payments after swaps. Equity financing was substantial: the company issued 4.4 million shares under its ATM program for $164.4 million gross and 2.7 million shares through its dividend reinvestment plan for $99.8 million gross. Subsequent to quarter end, the company closed an acquisition of 45 U.K. and Jersey facilities for total consideration of £259.8 million. Operator credit quality remained the central risk. Twenty operators were on a cash basis of revenue recognition, representing 18.6% of total revenues for the quarter. Maplewood short-paid $6.0 million of $19.6 million due in the quarter and short-paid a further $2.1 million in April 2025; its $320 million revolver is on non-accrual, with the amortized cost basis of $263.6 million and an internal risk rating of 5. Genesis failed to make its March 2025 rent and one loan interest payment, and LaVie is in Chapter 11 with a confirmed plan. Management reported that disclosure controls were effective as of March 31, 2025.

May 2, 2025
8-K

Omega Healthcare Investors 8-K Report, Financial Results (May 1, 2025)

Omega Healthcare Investors, Inc. (NYSE: OHI) reported first quarter 2025 results on May 1, 2025, in a press release furnished as Exhibit 99.1 under Item 2.02. Net income for the quarter was $112 million, or $0.33 per diluted share, compared to $69 million, or $0.27 per share, a year earlier. Nareit FFO was $184 million ($0.62 per share) and Adjusted FFO was $221 million ($0.75 per share), up from $176 million ($0.68 per share) in Q1 2024. Revenues totaled $276.8 million, and the company's indebtedness was $4.5 billion at a weighted-average annual interest rate of 4.6% as of March 31, 2025. The company raised its 2025 Adjusted FFO guidance to between $2.95 and $3.01 per share, from $2.90 to $2.98 previously. The guidance reflects $423 million of new investments completed through April 2025, including $344 million of U.K. and Jersey acquisitions in April, which the company assumes will be funded with equity issuances. During the quarter, the company issued 7 million common shares for gross proceeds of $264 million, repaid $400 million of senior notes at maturity, and extended its $1.45 billion revolving credit facility to October 30, 2025. The release also addressed operator credit risk. In March 2025, Genesis Healthcare did not pay its $4.2 million contractual rent and missed an interest payment on one of three loans; the company drew $4.3 million on a letter of credit. Genesis paid full contractual rent and interest in April 2025. The company cited its trailing 12-month EBITDAR coverage for Genesis of above 1.6x and noted $118 million of term loan exposure to Genesis. The company also declared a quarterly dividend of $0.67 per share, payable May 15, 2025.

May 1, 2025
10-K

Omega Healthcare Investors Annual Report, Year Ended Dec 31, 2024

Omega Healthcare Investors, Inc. ("Parent") is a Maryland corporation that invests in healthcare-related real estate in the U.S. and the U.K., operating as a REIT with one reportable segment. At December 31, 2024, its portfolio included 1,026 healthcare facilities operated by 87 third-party operators across 42 states and the U.K., with real estate investments of approximately $10.1 billion. Total revenues rose to $1,051.4 million in 2024 from $949.7 million in 2023, and net income was $417.8 million versus $248.8 million. Nareit FFO was $733.9 million in 2024 compared with $591.2 million in 2023. The company acquired 114 facilities for $740.5 million in 2024, including the remaining 51% interest in the Cindat Joint Venture for $364.9 million, and raised $1.2 billion of gross proceeds through its ATM Program and DRCSPP. Credit and operator stress remained significant. Twenty-one operators were on a cash basis of revenue recognition, representing 20.5% of total 2024 revenues. Maplewood continued to short-pay rent, and its Maplewood Revolver had an amortized cost basis of $263.6 million, which the filing says could result in a substantial loss if the proposed transition is not completed. LaVie Care Centers filed Chapter 11 in June 2024, and a plan of reorganization was confirmed in December 2024. Total debt was $4.9 billion, with a weighted average interest rate of 4.6%, and the company had $518.3 million of cash and $1.45 billion of revolver availability at year-end. Management reported effective internal control over financial reporting, and Ernst & Young issued an unqualified opinion.

Feb 13, 2025
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Feb 5, 2025)

Omega Healthcare Investors, Inc. reported fourth quarter 2024 net income of $116 million, or $0.41 per common share, compared with $57 million, or $0.22 per share, in Q4 2023. Nareit FFO for the quarter was $196 million ($0.68 per share) and Adjusted FFO (AFFO) was $214 million ($0.74 per share), up from $173 million ($0.68 per share) a year earlier. For full year 2024, net income was $418 million ($1.55 per diluted share), Nareit FFO was $734 million ($2.71 per share), and AFFO was $778 million ($2.87 per share), compared with $249 million ($1.00 per diluted share), $591 million ($2.36 per share), and $699 million ($2.79 per share) in 2023. Omega completed $340 million of new investments in Q4 2024, comprising $179 million of real estate acquisitions and $162 million of real estate loans, and $1.1 billion of new investments for the full year. The company issued 34 million common shares for $1.2 billion in gross proceeds during 2024. As of December 31, 2024, it had $4.9 billion of outstanding indebtedness at a weighted-average annual interest rate of 4.6%, $518.3 million of cash and cash equivalents, and $1.45 billion of undrawn revolving credit capacity. The company repaid $400 million of 4.50% senior notes on January 15, 2025 using balance sheet cash, and extended the maturity of its $1.45 billion revolver and $50 million term loan to October 30, 2025. For 2025, Omega expects Adjusted FFO of $2.90 to $2.98 per diluted share. Guidance assumes $56 million of asset sales, repayment of the $400 million senior notes due 2025 and a $231 million secured mortgage loan in November 2025, and balance sheet cash of approximately $600 million at December 31, 2025. The board declared a quarterly dividend of $0.67 per share on January 29, 2025.

Feb 5, 2025
8-K

Omega Healthcare Investors 8-K Report, Executive Changes (Jan 6, 2025)

Omega Healthcare Investors, Inc. (NYSE: OHI) announced leadership changes effective January 1, 2025. Matthew Gourmand, previously Senior Vice President of Corporate Strategy & Investor Relations, was appointed President, and Vikas Gupta, previously Senior Vice President of Acquisitions & Development, was appointed Chief Investment Officer. Both were approved for new employment agreements running through December 31, 2027, with annual base salaries of $550,000 for Mr. Gourmand and $525,000 for Mr. Gupta, subject to annual review for possible increase. Each agreement sets the high-performance annual bonus opportunity at 125% of base salary and provides severance of two times the sum of base salary and the three-year average annual bonus, plus 18 months of employer-paid group healthcare premiums, upon termination without cause or for good reason. Both executives are also subject to two-year post-termination non-competition and non-solicitation covenants. The filing also discloses the departure of Daniel J. Booth, Chief Operating Officer, whose employment ends January 2, 2025. Under a Transition Agreement and Release, Mr. Booth receives payments and benefits due upon a termination without cause under his employment agreement, with his previously granted equity incentives vesting prorated through January 1, 2026, and certain continued supplemental life insurance benefits. Separately, under a Consulting Agreement dated January 3, 2025, he will provide consulting and advisory services through January 1, 2026 for a fee of $10,000 per month. All separation benefits are conditioned on a general release of claims and continued compliance with post-termination covenants. Additionally, the company amended the employment agreements of its other named executive officers to extend their terms by one year to December 31, 2027 and revise salaries following the Compensation Committee's annual review. The transitions are part of the company's ongoing succession planning, according to CEO Taylor Pickett, who described the appointments as the next stage of growth for the company.

Jan 6, 2025
10-Q

Omega Healthcare Investors Quarterly Report for Q3 Ended Sep 30, 2024

Omega Healthcare Investors, Inc. ("Parent") reported its Form 10-Q for the quarter ended September 30, 2024. Total revenues for the three months ended September 30, 2024 were $276.0 million, up from $242.0 million a year earlier, and net income available to common stockholders was $111.8 million, or $0.42 per diluted share, versus $91.4 million, or $0.37, in the prior-year quarter. For the nine months, revenues were $772.1 million and net income available to common stockholders was $293.0 million ($1.14 diluted EPS). Nareit FFO was $196.1 million for the quarter and $538.3 million for the nine months, compared with $161.0 million and $462.3 million in the prior-year periods. Gains on asset sales were much smaller in 2024 ($11.3 million for the nine months versus $70.0 million in 2023), so the earnings improvement is driven largely by rental and interest income growth. The company's balance sheet grew to $9.57 billion in total assets at September 30, 2024, supported by about $801.2 million of common stock issuance over the nine months and the July 2024 acquisition of the remaining 51% interest in the Cindat Joint Venture, which added 63 U.K. facilities. Total debt was $4.86 billion, and the filing states that $400 million of 4.50% senior notes mature in January 2025, which management expects to repay using cash, the $1.45 billion revolver and the 2024 ATM program. Cash and cash equivalents were $342.4 million. Operator credit concerns remain the central risk. Maplewood's $263.6 million revolving loan, 18.9% of real estate loan amortized cost, is subject to a settlement and transition that still requires regulatory approvals, and the filing notes a substantial loss is possible if the transition is not completed. LaVie entered Chapter 11 in June 2024, and 18 operators were on a cash basis of revenue recognition, representing 18.6% of nine-month revenues. Quarterly dividends were maintained at $0.67 per share, with a dividend declared October 25, 2024.

Oct 31, 2024
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Oct 30, 2024)

Omega Healthcare Investors, Inc. (NYSE: OHI) reported third quarter 2024 results in a press release furnished as Exhibit 99.1 to this Form 8-K. Net income was $115 million, or $0.42 per common share, compared with $94 million, or $0.37 per share, in Q3 2023. Nareit FFO was $196 million ($0.71 per share) versus $161 million ($0.63), and Adjusted FFO (AFFO) was $203 million ($0.74 per share) versus $182 million ($0.71). FAD was $192 million ($0.70 per share) versus $174 million ($0.68). Revenues rose $34.0 million to $276.0 million, driven mainly by new investments and operator restructurings, while expenses fell $31.2 million to $163.3 million, reflecting lower impairments, a recovery in credit loss provisions, and lower depreciation and interest expense. The company invested $834 million year-to-date through October 30, 2024, including the $365 million acquisition of the remaining 51% interest in the Cindat joint venture, which covers 63 U.K. facilities. Omega issued 14 million common shares in Q3 for gross proceeds of $530 million. It raised its 2024 AFFO per share guidance to $2.84 to $2.86 from $2.78 to $2.84. Management also noted deleveraging. As of September 30, 2024, the company had $4.9 billion of outstanding indebtedness at a weighted-average annual interest rate of 4.6%, $342.4 million of cash, and $1.45 billion of undrawn revolver capacity. The Board declared a quarterly dividend of $0.67 per share, payable November 15, 2024. Operator credit remains a watch item. LaVie Care Centers filed for Chapter 11 in June 2024; Omega committed $10 million of debtor-in-possession financing, of which $4.5 million was drawn, and LaVie paid full monthly contractual rent of $3.0 million from June through October 2024. Maplewood is transitioning to its existing management team, subject to regulatory approvals, and paid $12.1 million of rent in Q3 2024. The company also recorded an $8.6 million net impairment on five facilities and held 15 facilities classified as assets held for sale with a net book value of $76.0 million.

Oct 30, 2024
8-K

Omega Healthcare Investors 8-K Report, Corporate Update (Sep 6, 2024)

On September 6, 2024, Omega Healthcare Investors, Inc. entered into a new at-the-market equity offering sales agreement with a group of Sales Agents, Forward Sellers and Forward Purchasers, under which it may sell common stock (par value $0.10 per share) with an aggregate gross sales price not to exceed $1,250,000,000. On the same date, the company terminated its prior at-the-market sales agreement dated May 20, 2021. The Securities will be offered under an automatic shelf registration statement on Form S-3 (No. 333-277916) and a prospectus supplement dated September 6, 2024. The company may sell Issuance Shares through the Sales Agents, either as agents or directly to them as principals, and may enter into forward sale agreements in which Forward Purchasers borrow and sell shares through Forward Sellers. Sales are made at prevailing market prices on the New York Stock Exchange or as otherwise permitted, and the company has no obligation to sell any securities and may suspend offers at any time. Sales Agents may receive compensation of up to 2.0% of the gross sales price of shares sold through them, and Forward Sellers may receive commissions of up to 2.0% in the form of a reduced initial forward sale price. The company expects to physically settle forward sale agreements by delivering shares and receiving proceeds on settlement dates no later than two years from entry into each agreement, but it may elect cash or net share settlement, in which case it may receive no proceeds and may owe cash or shares to the Forward Purchaser. The filing also notes that several Sales Agents and their affiliates have had and may have other commercial banking and investment banking relationships with the company and its subsidiaries. Exhibits include the sales agreement, a legal opinion from Shapiro Sher Guinot & Sandler, P.A., and a tax opinion from Bryan Cave Leighton Paisner LLP.

Sep 6, 2024
10-Q

Omega Healthcare Investors Quarterly Report for Q2 Ended Jun 30, 2024

Omega Healthcare Investors, Inc. reported net income available to common stockholders of $113.9 million, or $0.46 per basic share, for the three months ended June 30, 2024, compared with $59.9 million, or $0.25 per share, in the prior-year quarter. For the six months, net income available to common stockholders was $181.2 million ($0.73 basic per share). Total revenues were $252.7 million for the quarter and $496.0 million for the six months, and Nareit FFO was $189.1 million for the quarter and $342.2 million for the six months. Total assets were $8.85 billion at June 30, 2024, with cash and cash equivalents down to $35.2 million from $442.8 million at December 31, 2023, after repayment of $400 million of 4.95% senior notes in April 2024. The filing highlights significant credit concerns tied to operators. Maplewood Senior Living is short-paying rent, and Omega accelerated its $291.2 million revolving credit facility after issuing a May 2024 demand letter; a settlement agreement dated July 31, 2024 is subject to probate court and regulatory approvals. The amortized cost basis of the Maplewood loan was $263.6 million, or 18.0% of total real estate loans receivable. LaVie Care Centers filed Chapter 11 in June 2024, and Omega committed $10 million of a $20 million DIP financing facility, with a $7.8 million credit loss provision recorded in the quarter on LaVie loans. Eighteen operators were on a cash basis of revenue recognition, representing 18.6% of total revenues for the six months. Subsequent to quarter-end, Omega acquired the remaining 51% interest in the Cindat Joint Venture for $97.4 million in cash, assuming a $243.2 million mortgage loan, and the company declared a $0.67 per share dividend payable August 15, 2024.

Aug 2, 2024
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Aug 1, 2024)

Omega Healthcare Investors, Inc. (NYSE: OHI) reported second quarter 2024 net income of $117 million, or $0.45 per diluted share, compared with $62 million, or $0.25 per share, in the second quarter of 2023. Nareit FFO was $189 million, or $0.72 per share, up from $155 million, or $0.63 per share. Adjusted FFO (AFFO) was $185 million, or $0.71 per share, compared with $183 million, or $0.74 per share, a year earlier. Revenues were $252.7 million, up $2.6 million, and expenses were $149.9 million, down $51.5 million, primarily due to lower provision for credit losses, impairments, depreciation and amortization, and interest expense. The company completed $221 million of new investments in the quarter and $648.1 million year-to-date through July 31, 2024. The largest July transaction was the acquisition of the remaining 51% equity interest in the Cindat joint venture for $97.4 million in cash plus assumption of a $243.2 million mortgage loan, bringing Omega's total investment in 63 U.K. facilities to approximately $435.9 million. Management raised 2024 AFFO guidance to $2.78 to $2.84 per diluted share from $2.70 to $2.80. The company also declared a quarterly dividend of $0.67 per share, payable August 15, 2024. Operator credit developments were mixed. LaVie Care Centers filed for Chapter 11 in June 2024, and Omega committed $10 million of debtor-in-possession financing, with $4.5 million outstanding at June 30, 2024. LaVie is required to pay full contractual rent during bankruptcy, and paid approximately $3.0 million in each of June and July 2024. An agreement to transition Maplewood Senior Living to its existing management team is subject to court approval. At June 30, 2024, Omega had $4.7 billion of outstanding indebtedness at a weighted-average interest rate of 4.3%, $35.2 million of cash, and $1.4 billion of undrawn revolving credit capacity.

Aug 1, 2024
8-K

Omega Healthcare Investors 8-K Report, Shareholder Vote Results (Jun 7, 2024)

Omega Healthcare Investors, Inc. ("Omega") held its Annual Meeting of Stockholders on June 7, 2024, according to this Current Report on Form 8-K. Holders of 198,889,951 shares of common stock were present in person or represented by proxy, representing approximately 80.54% of the total outstanding common stock as of the record date. Stockholders voted on three proposals. All eight director nominees were elected: Kapila K. Anand, Craig R. Callen, Dr. Lisa C. Egbuonu-Davis, Barbara B. Hill, Kevin J. Jacobs, C. Taylor Pickett, Stephen D. Plavin, and Burke W. Whitman. Stockholders also ratified the selection of Ernst & Young LLP as Omega's independent auditor for fiscal year 2024, with 190,372,644 votes for and 7,992,692 against. In a separate advisory vote, stockholders approved Omega's executive compensation, with 145,513,626 votes for, 8,549,668 against, and 1,081,137 abstentions. The filing reports voting results only. It contains no financial results, guidance, or transaction disclosures. Plavin received the most votes against among the director nominees, at 8,793,871, while the other nominees drew between 1,446,209 and 3,667,932 votes against.

Jun 7, 2024
8-K

Omega Healthcare Investors 8-K Report, Regulation FD Disclosure (Jun 3, 2024)

Omega Healthcare Investors, Inc. (NYSE: OHI) furnished a Form 8-K on June 3, 2024 to announce an update on the restructuring of its operator LaVie Care Centers and to disclose a revised Operator Updates slide in its June 2024 Investor Presentation, posted to its website. The press release (Exhibit 99.1) states that LaVie has filed for Chapter 11 bankruptcy protection in the Northern District of Georgia. Omega described the filing as a necessary step toward an operationally solvent and sustainable entity with enhanced liquidity and a strengthened balance sheet. Omega stated it has elected to commit $10 million to fund 50% of the expected debtor-in-possession (DIP) financing to support liquidity for operating the facilities during bankruptcy. Omega said it believes the current cash flow from its remaining LaVie portfolio is sustainable and will support long-term annualized rent of $36 million. During bankruptcy, LaVie is required, subject to court approval, to pay Omega monthly rent of $3 million on the 30 properties it continues to lease from Omega. The proposed DIP budget anticipates confirmation of a plan or sale of assets by the end of 2024, but Omega cautioned that this timeline is subject to bankruptcy court approval and the complexities of Chapter 11 proceedings. The information is furnished under Item 7.01 (Regulation FD) and is not deemed filed for purposes of Section 18 of the Exchange Act.

Jun 3, 2024
10-Q

Omega Healthcare Investors Quarterly Report for Q1 Ended Mar 31, 2024

Omega Healthcare Investors, Inc. ("Parent"), a Maryland REIT that invests in healthcare real estate in the U.S. and U.K., reported net income of $69.3 million for the quarter ended March 31, 2024, compared with $36.8 million in the prior-year quarter. Net income available to common stockholders was $67.4 million, or $0.27 per diluted share, versus $0.15 a year earlier. Total revenues rose to $243.3 million from $218.2 million, driven mainly by rental income of $206.9 million and interest income of $35.8 million. The prior-year quarter included a $12.5 million Maplewood option termination fee that reduced rental income, which partly explains the year-over-year rental income increase. Credit quality remained a central theme. Twenty operators were on a cash basis of revenue recognition, representing 18.4% of total revenues for the quarter. Maplewood short-paid rent, and its loan was moved to a higher internal risk rating, contributing to a provision for credit losses of $8.5 million. Total impairments were $5.3 million, and the allowance for credit losses on total loans and commitments rose to $229.8 million. Total assets were $9.01 billion, total debt was $5.03 billion, and cash and cash equivalents were $361.8 million. Subsequent to quarter end, the company repaid the $400 million 4.95% senior notes due April 1, 2024, using cash and revolver proceeds. The company also raised $32.4 million of gross proceeds through its ATM program and DRIP and declared a $0.67 per share dividend payable May 15, 2024. Management stated it expects its sources of liquidity to fund cash needs over the next twelve months and noted that the 2025 senior notes maturity can be addressed with existing liquidity sources.

May 3, 2024
8-K

Omega Healthcare Investors 8-K Report, Financial Results (May 2, 2024)

Omega Healthcare Investors, Inc. ("Omega") furnished a press release reporting its results for the quarter ended March 31, 2024. Net income was $69 million, or $0.27 per common share, versus $37 million, or $0.15 per share, in Q1 2023. Nareit FFO was $153 million ($0.60 per share), and Adjusted FFO was $176 million ($0.68 per share), compared with $160 million ($0.66 per share) a year earlier. Total revenues were $243.3 million, up $25.1 million year over year, driven by operator restructurings and transitions and new investments. Expenses declined $25.8 million, mainly from lower impairments, depreciation and amortization, and interest expense. During the quarter Omega completed $75 million of new investments and issued 1 million common shares for $33 million in gross proceeds. It repaid a $400 million senior note maturing April 1, 2024, and reported $361.8 million of cash and $1.4 billion of undrawn revolver capacity as of March 31, 2024. Total indebtedness was $5.1 billion at a weighted-average annual interest rate of 4.4%. Guardian failed to make its first-quarter rent payments, and the remaining six Guardian facilities were transitioned to a new operator in April 2024 with minimum initial contractual rent of $5.5 million per annum. Management affirmed 2024 Adjusted FFO guidance of $2.70 to $2.80 per diluted share and declared a quarterly dividend of $0.67 per share payable May 15, 2024. The press release also noted that Omega expects incremental cash payments from the LaVie and Maplewood portfolios as restructurings conclude, and criticized the recently finalized federal minimum staffing rule for skilled nursing facilities.

May 2, 2024
8-K

Omega Healthcare Investors 8-K Report, Corporate Update (Apr 15, 2024)

Omega Healthcare Investors, Inc. filed this Current Report to disclose that on April 2, 2024, the District Court for the District of Maryland granted preliminary approval to a proposed settlement of the shareholder derivative action Wojcik v. Omega Healthcare Investors, Inc., et al., Case No. 1:20-cv-03491. The stipulation of settlement is dated February 22, 2024, and involves plaintiff Robert Wojcik, the Company as nominal defendant, and the named individual defendants. The Court has scheduled a final approval hearing for June 24, 2024, at 2:00 p.m. Eastern Time. On April 15, 2024, the Company posted the Notice of Proposed Settlement and the Stipulation of Settlement to the Governance section of its investor website, and filed both as Exhibits 99.1 and 99.2. The settlement is non-monetary for the Company. Its principal term is the adoption of corporate governance reforms relating to diversity, discrimination, race, gender, and social justice, which the Board must implement within sixty days of the Effective Date and maintain for no less than two years. The reforms cover an ESG Steering Committee, a new independent director appointed in 2021, director and senior leadership candidate pool processes, diversity training, and board skills and diversity reporting. Omega's insurers are to pay $850,000 in plaintiff's attorneys' fees and expenses, subject to court approval, and the plaintiff may seek a service award of up to $2,000. The settlement does not resolve the Stourbridge and Swan derivative actions, which the parties have agreed to address in a separate stipulation. The filing states that the defendants deny all wrongdoing and that the settlement is not an admission of liability. Objections by current shareholders are due June 3, 2024, and the settlement becomes effective only after the judgment is entered and becomes final.

Apr 15, 2024
8-K

Omega Healthcare Investors 8-K Report, Corporate Update (Mar 14, 2024)

On March 14, 2024, Omega Healthcare Investors, Inc. filed an automatic shelf registration statement on Form S-3ASR (File No. 333-277916) to replace its prior automatic shelf registration statement (File No. 333-256084, filed May 13, 2021). The prior registration statement was terminated upon the new one becoming effective on March 14, 2024. This filing is administrative in nature and does not itself disclose financial results or operating performance. In connection with the new registration statement, the company filed two prospectus supplements on the same date. The first, the DRCSPP Prospectus Supplement, continues the offering of common stock under the company's Dividend Reinvestment and Common Stock Purchase Plan, previously covered by an August 5, 2021 prospectus supplement, and registers an aggregate of 14,152,369 shares of common stock for issuance. The second, the ATM Prospectus Supplement, continues the at-the-market equity offering under its existing sales agreement with multiple sales agents, forward sellers and forward purchasers, previously covered by a May 20, 2021 prospectus supplement. The filing states that it does not constitute an offer to sell or a solicitation of an offer to buy securities. The filing attaches legal opinions from Shapiro Sher Guinot & Sandler, P.A. and Bryan Cave Leighton Paisner LLP, along with related consents, and includes the cover page interactive data file. It was signed by Robert O. Stephenson, Chief Financial Officer, Treasurer and Assistant Secretary.

Mar 14, 2024
8-K

Omega Healthcare Investors 8-K Report, Corporate Update (Mar 12, 2024)

Omega Healthcare Investors, Inc. filed this Form 8-K on March 12, 2024 to report that the Circuit Court for Baltimore City granted preliminary approval, on February 28, 2024, to a proposed settlement of certain shareholder derivative actions. The settlement, set out in a Stipulation of Settlement dated February 22, 2024, involves plaintiffs Stourbridge Investments LLC, Phillip Swan, Tom Bradley, and Sarah Smith, with the Company as nominal defendant. The actions cover the Maryland State Action (Swan v. Pickett and Bradley v. Callen) and the New York Federal Action (Stourbridge Investments LLC v. Callen). The Court has scheduled a final approval hearing for May 21, 2024, at 2:00 p.m. Eastern Time. The settlement's operative consideration is non-monetary. Under Exhibit A to the Stipulation, the Company agrees to adopt corporate governance reforms within 60 days after the Effective Date, and these reforms remain in effect for a three-year Effective Term. The reforms cover areas including credit risk oversight by the Chief Operating Officer, a Disclosure Committee, audit committee enhancements, insider trading policy changes, and clawback policy updates. The Notice states there is no claims procedure and no payment to individual shareholders. The Company, or its insurers, agreed to pay plaintiffs' counsel attorneys' fees and expenses of $1,950,000, subject to court approval. The defendants deny all wrongdoing, and the Stipulation states that it is not an admission of liability. For investors, the filing is primarily a governance and procedural disclosure. It sets out the terms of the derivative settlement, the approval timetable, and the governance commitments the Company will adopt. The filing does not state any financial impact on the Company beyond the fee amount.

Mar 12, 2024
10-K

Omega Healthcare Investors Annual Report, Year Ended Dec 31, 2023

Omega Healthcare Investors, Inc. ("Parent") is a Maryland corporation that invests in healthcare-related real estate in the U.S. and the U.K., with a portfolio at December 31, 2023 of 891 healthcare facilities operated by 74 third-party operators across 42 states and the U.K. Total revenues were $949.7 million in 2023, up from $878.2 million in 2022, driven primarily by rental income of $825.4 million (up from $750.2 million), though the filing attributes much of the improvement to fewer straight-line rent write-offs ($8.1 million in 2023 versus $122.9 million in 2022). Net income was $248.8 million in 2023 versus $438.8 million in 2022, reflecting lower gains on asset sales ($79.7 million versus $360.0 million) and $91.9 million of real estate impairments. Nareit FFO was $591.2 million, compared with $460.5 million in 2022. Operator stress remains the central investor concern. As of December 31, 2023, 19 operators were on a cash basis of revenue recognition, representing 23.9% of total revenues (excluding write-offs). Several operators, including LaVie, Maplewood and Guardian, short-paid or deferred rent during 2023, and the company restructured their leases and loans, applied security deposits, and sold facilities. Total debt was $5.1 billion, with a weighted average interest rate of 4.4%, and the company reported cash and cash equivalents of $442.8 million. Stockholders' equity was $3.57 billion at year end. The filing also highlights regulatory exposure, including CMS proposed minimum staffing rules for skilled nursing facilities and the expiration of the 6.2% Medicaid FMAP add-on. The 2024 dividend was declared at $0.67 per share quarterly, consistent with the $2.68 annual rate paid in 2023.

Feb 12, 2024
8-K

Omega Healthcare Investors 8-K Report, Financial Results (Feb 7, 2024)

Omega Healthcare Investors, Inc. (NYSE: OHI) reported fourth-quarter 2023 net income of $57 million, or $0.22 per common share, up from $47 million, or $0.19 per share, in the fourth quarter of 2022. Nareit FFO was $129 million, or $0.50 per share, compared with a loss of $30 million, or $0.13 per share, a year earlier. Adjusted FFO (AFFO) was $173 million, or $0.68 per share, versus $177 million, or $0.73 per share, and FAD was $163 million, or $0.64 per share, versus $171 million, or $0.70 per share. For full-year 2023, net income was $249 million, or $1.00 per share, compared with $439 million, or $1.80 per share, in 2022. Full-year AFFO was $699 million, or $2.79 per share, versus $730 million, or $2.99 per share, in 2022. Management said operating performance is improving, with occupancy above 80% and EBITDAR coverage of 1.28x, a post-pandemic high. The company expects first- and second-quarter 2024 earnings to remain affected by operator restructurings, with improvement later in the year. It provided 2024 AFFO guidance of $2.70 to $2.80 per diluted share, its first annual AFFO guidance since the pandemic. The board declared a quarterly dividend of $0.67 per share, payable February 15, 2024. The filing flags operator risk, including Guardian Healthcare's failure to make its fourth-quarter contractual rent payments. The company is in discussions to sell or re-lease the six remaining Guardian facilities. Management also cited the pending CMS final rule on minimum staffing as the primary remaining concern. At year-end, the company reported $5.1 billion of outstanding indebtedness at a weighted-average annual interest rate of 4.4%, $442.8 million of cash, and $1.43 billion of undrawn revolver capacity.

Feb 7, 2024
8-K

Omega Healthcare Investors 8-K Report, Executive Changes (Jan 2, 2024)

Omega Healthcare Investors, Inc. (OHI) filed this Form 8-K on January 2, 2024 to report an amendment to the employment agreements of its named executive officers. As of January 1, 2024, the Company entered into amendments with each named executive officer that extend the term of their employment agreements by one year, to December 31, 2026, and revise their annual base salaries following the annual review conducted by the Compensation Committee of the Board of Directors. The filing states that no other material amendments were made to these employment agreements. The report is limited to Item 5.02 (Departure of Directors or Certain Officers; Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). The only listed exhibit is Exhibit 104, the Cover Page Interactive Data File embedded in the Inline XBRL document. The filing does not disclose the specific salary figures or the amounts of any compensation changes. For investors, the filing signals management continuity, since the named executive officers' employment terms now run through December 31, 2026. The filing contains no information on financial results, operations, or other corporate developments.

Jan 2, 2024
8-K

Omega Healthcare Investors 8-K Report, Regulation FD Disclosure (Dec 4, 2023)

Omega Healthcare Investors, Inc. (NYSE: OHI) filed a Current Report on Form 8-K on December 4, 2023, furnishing information under Item 7.01 (Regulation FD Disclosure). The Company announced that it had posted an updated investor presentation titled "December 2023 Investor Presentation" to its website, in the Investor Relations and News & Events sections. The update consists of a revised Operator Updates slide, and the presentation is in conjunction with the Jefferies Real Estate Conference. The presentation will remain on the Company's website for at least thirty days. The filing is a limited disclosure. The Company describes the information as furnished rather than filed, meaning it is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings. The press release, filed as Exhibit 99.1, describes Omega as a real estate investment trust investing in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities, with assets operated by a diverse group of healthcare companies predominantly under a triple-net lease structure, spanning all US regions and the UK. The filing does not disclose new financial results, dividends, guidance, or transactions. Its investor relevance lies mainly in the revised operator information shown in the updated presentation, which the filing does not detail. Investors seeking the substance of the change should review the presentation itself on the Company's website.

Dec 4, 2023
10-Q

Omega Healthcare Investors Quarterly Report for Q3 Ended Sep 30, 2023

Omega Healthcare Investors, Inc. ("Parent"), a Maryland REIT that invests in healthcare real estate in the U.S. and U.K., reported net income available to common stockholders of $91.4 million ($0.37 per diluted share) for the three months ended September 30, 2023, compared with $102.3 million ($0.43) a year earlier. For the nine months, net income available to common stockholders was $187.2 million ($0.78 per diluted share), versus $381.3 million ($1.60) in the prior-year period. Total revenues were $242.0 million for the quarter and $710.4 million for the nine months. Gains on asset sales were $44.1 million in the quarter and $70.0 million year to date, while impairments on real estate properties totaled $27.9 million and $88.0 million for the same periods. The filing shows continued operator stress. Eighteen operators were on a cash basis of revenue recognition as of September 30, 2023, representing 25.1% of total revenues (excluding write-offs) for the nine months. Maplewood short-paid rent in multiple months, Guardian did not pay rent in August and September, and LaVie paid $7.4 million against $20.7 million due in the third quarter. The company also restructured several operator relationships and extended significant loans. Total assets were $9.43 billion and total equity $3.86 billion at September 30, 2023, with total debt of $5.29 billion. Cash and cash equivalents rose to $554.7 million, supported by a new $400 million 2025 senior unsecured term loan (upsized by $28.5 million) and the repayment of $350 million of 4.375% notes due August 2023. Subsequent to quarter end, the company sold 29 facilities previously leased to LaVie for $305.2 million in purchase consideration, consisting of $91.9 million in gross cash proceeds and $213.3 million in HUD mortgage pay-offs, and amended the LaVie master lease to reduce monthly rent to $3.4 million. The Board declared a $0.67 per share quarterly dividend payable November 15, 2023.

Nov 3, 2023